A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Endeavor Biomedicines, Inc.
University Health Network, Toronto
Children's Oncology Group
University of Southern California
National Cancer Institute (NCI)
Seattle Children's Hospital
GlaxoSmithKline
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
Valo Therapeutics Oy